# Sanyou Bio

> Shanghai antibody-drug discovery and development platform combining large molecular libraries, AI-assisted design and wet-lab validation.

## Why it is interesting

Sanyou's November 9, 2026 company-issued Series C was funded exclusively by Zero2IPO Industry Investment. The exact disclosed amount is qualified as 'nearly' an original-currency amount, corresponding to less than about $15M at the November 9 ECB fixing. Earlier financing rounds and a February 2026 shareholder transfer are distinct; partnership and clinical-development claims need careful maturity caveats.

## Profile

- **Latest funding:** Series C (announced; legal close date not specified) — Under approximately $15M (USD converted estimate; not exact) (November 9, 2026)
- **Latest known valuation:** Undisclosed (November 9, 2026)
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-09
- **Latest funding investors:** Zero2IPO Industry Investment

## Key facts

- Issuer-announced November 9, 2026 Series C: less than approximately $15M converted (the original figure is expressly qualified); Zero2IPO Industry Investment sole investor.
- Company-reported lifetime funding is under approximately $45M in converted USD, not a new financing tranche.
- Historical Series A in May 2020, Series B in June 2021 and Series B+ in August 2022 are distinct; amounts not precisely established.
- AI-STAL + SAI-DA support target-to-antibody candidate screening and optimization using computational and laboratory processes.
- Clicklinks launched August 2026 for collaborative drug discovery; collaborations do not establish regulatory approval or revenue.

## Funding history

- Series C (announced; legal close date not specified) · Under approximately $15M (USD converted estimate; not exact) · November 9, 2026
  Source: https://www.prnewswire.com/news-releases/sanyou-bio-secures-exclusive-series-c-investment-from-zero2ipo-industry-investment-bringing-total-funding-to-nearly-rmb-300-million-302932833.html
- Series B+ (announced) · Amount undisclosed in USD/EUR · August 2, 2022
  Source: https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-closed-the-series-b-financing-round-of-tens-of-millions-of-rmb-led-by-huatai-zijin-301598027.html
- Series B (announced) · Amount undisclosed · June 26, 2021
  Source: https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-completes-series-b-financing-and-secures-its-leading-role-in-innovative-antibody-drug-discovery-301320548.html
- Series A (historical announcement) · Amount undisclosed · May 2020
  Source: https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-completes-series-b-financing-and-secures-its-leading-role-in-innovative-antibody-drug-discovery-301320548.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 9, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/sanyou-bio